TITLE:
CPG 7909 Injection in Non-Small Cell Lung Cancer

CONDITION:
Carcinoma, Non-Small Cell Lung

INTERVENTION:
CPG 7909

SUMMARY:

      Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a
      taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol
      therapy will be administered until disease progression or intolerable toxicity. CpG 7909
      Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle
      (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will
      undergo complete disease evaluation at the end of every other treatment cycle until disease
      progression.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer that is beyond
             surgical cure or that is metastatic (Stage IIIB or IV according to AJCC).

          -  Patients must have measurable disease according to the RECIST criteria.

        Exclusion Criteria:

          -  Prior treatment with chemotherapy; patients may have received prior radiotherapy.

          -  Patients with suspected or known CNS metastases.
      
